The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
暂无分享,去创建一个
B. Roth | W. Kroeze | E. Lopez | Shamil Patel
[1] D. Woolley,et al. A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS. , 1954, Proceedings of the National Academy of Sciences of the United States of America.
[2] S. Gershon,et al. Clozapine--a potential antipsychotic agent without extrapyramidal manifestations. , 1974, Current therapeutic research, clinical and experimental.
[3] Richard J. Miller,et al. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism , 1974, Nature.
[4] H. L. Goldberg,et al. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. , 1979, The American journal of psychiatry.
[5] S H Snyder,et al. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. , 1979, Molecular pharmacology.
[6] J. Palacios,et al. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. , 1984, European journal of pharmacology.
[7] R. Glennon,et al. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.
[8] H. Meltzer,et al. Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin2 Receptors in Rat Cerebral Cortex , 1986, Journal of neurochemistry.
[9] B. Cohen,et al. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. , 1986, Life sciences.
[10] M. Cohen,et al. Contractile serotonergic receptor in rat stomach fundus. , 1987, The Journal of pharmacology and experimental therapeutics.
[11] B. Roth,et al. Multiple mechanisms of serotonergic signal transduction. , 1987, Life sciences.
[12] A. Doenicke,et al. POSSIBLE BENEFIT OF GR43175, A NOVEL 5-HT1-LIKE RECEPTOR AGONIST, FOR THE ACUTE TREATMENT OF SEVERE MIGRAINE , 1988, The Lancet.
[13] M. Caron,et al. The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor , 1988, Nature.
[14] G. Aghajanian,et al. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[15] E. sanders-Bush,et al. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. , 1988, The Journal of pharmacology and experimental therapeutics.
[16] S. Peroutka,et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. , 1989, European journal of pharmacology.
[17] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[18] M. Titeler,et al. Detection of a Novel Serotonin Receptor Subtype (5‐HT1E) in Human Brain: Interaction with a GTP‐Binding Protein , 1989, Journal of neurochemistry.
[19] G. Kennett,et al. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. , 1989, European journal of pharmacology.
[20] J. Bockaert,et al. BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. , 1989, European journal of pharmacology.
[21] T. Jessell,et al. The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[22] B. Wells,et al. Buspirone in the Treatment of Posttraumatic Stress Disorder , 1991, Pharmacotherapy.
[23] R. Myers,et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. , 1991, Science.
[24] J. Amsterdam,et al. Buspirone in major depression: a controlled study. , 1991, The Journal of clinical psychiatry.
[25] B. Roth,et al. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. , 1992, The Journal of pharmacology and experimental therapeutics.
[26] R. McGuffin,et al. Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. , 1992, Biochemical and biophysical research communications.
[27] T. Branchek,et al. Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Roth,et al. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors. , 1992, Molecular pharmacology.
[29] L L Iversen,et al. Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Woods,et al. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder , 1992, Biological Psychiatry.
[31] M. Erlander,et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.
[32] J. Kehne,et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. , 1993, The Journal of pharmacology and experimental therapeutics.
[33] D. Murphy,et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP , 1993, Biological Psychiatry.
[34] S. Woods,et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. , 1993, Archives of general psychiatry.
[35] D. Sibley,et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. , 1993, Molecular pharmacology.
[36] M. Mattei,et al. Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. , 1993, Molecular pharmacology.
[37] D. Sibley,et al. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. , 1993, The Journal of biological chemistry.
[38] Antagonists of 5-HT4 receptor-mediated responses in adult hippocampal neurons. , 1994, The Journal of pharmacology and experimental therapeutics.
[39] D. Sibley,et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.
[40] D. Nelson,et al. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. , 1994, Molecular pharmacology.
[41] R Hen,et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. , 1994, Science.
[42] I. Forbes,et al. In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist , 1994, British journal of pharmacology.
[43] R. Hen,et al. Regulation of [3H]5-HT release in raphe, frontal cortex and hippocampus of 5-HT1B knock-out mice , 1995, Neuroreport.
[44] David Julius,et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.
[45] G. Baxter,et al. Mediation by 5‐hydroxytryptamine2B receptors of endothelium‐dependent relaxation in rat jugular vein , 1995, British journal of pharmacology.
[46] P R Saxena,et al. Serotonin receptors: subtypes, functional responses and therapeutic relevance. , 1995, Pharmacology & therapeutics.
[47] G. Martin,et al. Classification and nomenclature of 5-HT receptors: a comment on current issues , 1995, Behavioural Brain Research.
[48] D. Sibley,et al. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry , 1995, Neuroscience.
[49] S. Yamawaki,et al. Chronic antidepressant exposure enhances 5-hydroxytryptamine7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. , 1996, Journal of Pharmacology and Experimental Therapeutics.
[50] P. Blier,et al. Sequential administration of augmentation strategies in treatment‐resistant obsessive‐compulsive disorder: preliminary findings , 1996, International clinical psychopharmacology.
[51] D. Sibley,et al. Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.
[52] C. Montigny,et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.
[53] T. Branchek,et al. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5‐ht7 receptor in rat brain , 1996, British journal of pharmacology.
[54] S. Garattini,et al. Pharmacology of ingestive behaviour. , 1996, The´rapie (Paris).
[55] P. Séguéla,et al. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. , 1996, Molecular pharmacology.
[56] J. Halford,et al. The 5-HT2 Receptor Agonist MK-212 Reduces Food Intake and Increases Resting but Prevents the Behavioural Satiety Sequence , 1997, Pharmacology Biochemistry and Behavior.
[57] R. Emeson,et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.
[58] R. Eglen,et al. RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.
[59] D. Middlemiss,et al. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[60] M. Rapport. The Discovery of Serotonin , 2015, Perspectives in biology and medicine.
[61] Kirk W. Johnson,et al. 5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.
[62] A. Brown,et al. SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.
[63] R. Hen,et al. 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. , 1997, Molecular pharmacology.
[64] T. Branchek,et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. , 1997, Life sciences.
[65] A. Sleight,et al. The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. , 1998, Molecular pharmacology.
[66] J. Bockaert,et al. 5‐HT4 Receptors: Gene, Transduction and Effects on Olfactory Memory , 1998, Annals of the New York Academy of Sciences.
[67] M. Jurzak,et al. The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells. , 1998, European journal of pharmacology.
[68] D. Middlemiss,et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity , 1998, British journal of pharmacology.
[69] L. Tecott,et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene , 1998, Nature Medicine.
[70] W. Kroeze,et al. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis , 1998, Biological Psychiatry.
[71] A. Sleight,et al. Involvement of 5‐HT6 receptors in nigro‐striatal function in rodents , 1998, British journal of pharmacology.
[72] R. Hen,et al. Putative 5‐ht5 Receptors: Localization in the Mouse CNS and Lack of Effect in the Inhibition of Dural Protein Extravasation , 1998, Annals of the New York Academy of Sciences.
[73] L. Phebus,et al. Serotonin in migraine: theories, animal models and emerging therapies. , 1998, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[74] A. Sleight,et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.
[75] R. Hen,et al. Absence of Fenfluramine-Induced Anorexia and Reduced c-fos Induction in the Hypothalamus and Central Amygdaloid Complex of Serotonin 1B Receptor Knock-Out Mice , 1998, The Journal of Neuroscience.
[76] R. Emeson,et al. Identification and Characterization of RNA Editing Events within the 5‐HT2C Receptor a , 1998, Annals of the New York Academy of Sciences.
[77] R. Hen,et al. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor , 1999, Psychopharmacology.
[78] P. Pauwels,et al. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. , 1999, The Journal of pharmacology and experimental therapeutics.
[79] John A. Peters,et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function , 1999, Nature.
[80] M. Geyer,et al. Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor , 1999, Neuron.
[81] A. Anand,et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial , 1999, Biological Psychiatry.
[82] L. Tecott,et al. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.
[83] Colleen M. Niswender,et al. RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.
[84] B. Roth,et al. Activation is Hallucinogenic and Antagonism is Therapeutic: Role of 5-HT2A Receptors in Atypical Antipsychotic Drug Actions , 1999 .
[85] J. Bockaert,et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.
[86] Johnson Gw,et al. Present and future of 5-HT receptor agonists as antimigraine drugs. , 1999 .
[87] R. Emeson,et al. Serotonin-2C Receptor Pre-mRNA Editing in Rat Brain andin Vitro by Splice Site Variants of the Interferon-inducible Double-stranded RNA-specific Adenosine Deaminase ADAR1* , 1999, The Journal of Biological Chemistry.
[88] T. Svensson,et al. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. , 1999, Science.
[89] T. Dawson,et al. Regulation of alternative splicing by RNA editing , 1999, Nature.
[90] P. Pauwels,et al. Present and future of 5-HT receptor agonists as antimigraine drugs. , 1999, Clinical neuropharmacology.